» Articles » PMID: 35692737

Improving Immunoassay Detection Accuracy of Anti-SARS-CoV-2 Antibodies Through Dual Modality Validation

Overview
Specialty Biotechnology
Date 2022 Jun 13
PMID 35692737
Authors
Affiliations
Soon will be listed here.
Abstract

A novel test strategy is proposed with dual-modality detection techniques for COVID-19 antibody detection. The full-length S protein of SARS-CoV-2 was chemically immobilized on a glass surface to capture anti-SARS-CoV-2 IgG in patient serum and was detected through either Electrochemical Impedance Spectroscopy (EIS) or fluorescence imaging with labeled secondary antibodies. Gold nanoparticles conjugated with protein G were used as the probe and the bound GNP-G was detected through EIS measurements. Anti-human-IgG conjugated with the fluorescent tag Alexa Fluor 488 was used as the probe for fluorescence imaging. Clinical SARS-CoV-2 IgG positive serum and negative controls were used to validate both modalities. For fluorescence-based detection, a high sensitivity was noticed with a quantification range of 0.01-0.1 A.U.C. and a LOD of 0.004 A.U.C. This study demonstrates the possibility of utilizing different measurement techniques in conjunction for improved COVID-19 serology testing.

Citing Articles

Faradaic Impedimetric Immunosensor for Label-Free Point-of-Care Detection of COVID-19 Antibodies Using Gold-Interdigitated Electrode Array.

Shoute L, Charlton C, Kanji J, Babiuk S, Babiuk L, Chen J Biosensors (Basel). 2024; 14(1).

PMID: 38248383 PMC: 10812953. DOI: 10.3390/bios14010006.

References
1.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

2.
Serre-Miranda C, Nobrega C, Roque S, Canto-Gomes J, Silva C, Vieira N . Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients. Int J Infect Dis. 2021; 104:661-669. PMC: 7817432. DOI: 10.1016/j.ijid.2021.01.038. View

3.
Selingerova I, Valik D, Gescheidtova L, Sramek V, cermakova Z, Zdrazilova-Dubska L . Interpretive discrepancies caused by target values inter-batch variations in chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG by MAGLUMI. J Med Virol. 2020; 93(3):1805-1809. DOI: 10.1002/jmv.26612. View

4.
Lippi G, Salvagno G, Pegoraro M, Militello V, Caloi C, Peretti A . Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays. Clin Chem Lab Med. 2020; 58(7):1156-1159. DOI: 10.1515/cclm-2020-0473. View

5.
Krajewski R, Golebiowska J, Makuch S, Mazur G, Agrawal S . Update on serologic testing in COVID-19. Clin Chim Acta. 2020; 510:746-750. PMC: 7491380. DOI: 10.1016/j.cca.2020.09.015. View